188 related articles for article (PubMed ID: 2498532)
1. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.
Kim HH; Lee C
J Urol; 1989 Jun; 141(6):1337-9; discussion 1339-40. PubMed ID: 2498532
[TBL] [Abstract][Full Text] [Related]
2. [Intravesical mitomycin for superficial tumors of the bladder: difficulties of cystoscopic monitoring].
Fourcade RO; Giuliano F
Ann Urol (Paris); 1988; 22(6):404-6. PubMed ID: 3146942
[TBL] [Abstract][Full Text] [Related]
3. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW
J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575
[TBL] [Abstract][Full Text] [Related]
4. Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: long-term results.
Hurle R; Manzetti A; Losa A; Micheli E; Ranieri A; Chinaglia D; Lembo A
Urol Int; 1998; 61(4):220-6. PubMed ID: 10364753
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer.
Tsushima T; Matsumura Y; Ozaki Y; Yoshimoto J; Ohmori H
Cancer Chemother Pharmacol; 1987; 20 Suppl():S72-6. PubMed ID: 3117400
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Giesbers AA; Van Helsdingen PJ; Kramer AE
Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144
[TBL] [Abstract][Full Text] [Related]
7. Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer.
Jauhiainen K; Alfthan O
Br J Urol; 1987 Jul; 60(1):54-9. PubMed ID: 3113524
[TBL] [Abstract][Full Text] [Related]
8. Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer.
Schwarzman MI; Johanson KE; Surya B; Brown J
Urology; 1988 Oct; 32(4):335-8. PubMed ID: 3140465
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
Pavlotsky A; Eidelman A; Barak F; Alon H; Horn Y
J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
[TBL] [Abstract][Full Text] [Related]
10. Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.
Hetherington JW; Newling DW; Robinson MR; Smith PH; Adib RS; Whelan P
Br J Urol; 1987 Mar; 59(3):239-41. PubMed ID: 3105631
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Tolley DA; Hargreave TB; Smith PH; Williams JL; Grigor KM; Parmar MK; Freedman LS; Uscinska BM
Br Med J (Clin Res Ed); 1988 Jun; 296(6639):1759-61. PubMed ID: 3136828
[TBL] [Abstract][Full Text] [Related]
12. Postoperative prophylactic intravesical instillation of cytosine arabinoside and mitomycin C in superficial bladder tumor. A follow-up study.
Omoto T; Kano M; Ariyoshi A; Momose S; Masaki Z; Morita I; Ishisawa N
Urology; 1982 Nov; 20(5):510-4. PubMed ID: 6815854
[TBL] [Abstract][Full Text] [Related]
13. Long-term observation after intravesical metaphylaxis with mitomycin C in patients with superficial bladder tumors.
Maier U; Höbarth K
Urology; 1991 May; 37(5):481-2. PubMed ID: 1902606
[TBL] [Abstract][Full Text] [Related]
14. Cytostatic intravesical instillation in patients with superficial bladder carcinoma for the prevention of recurrent tumors.
Huland H; Klöppel G; Otto U; Feddersen I; Brachmann W; Hubmann H; Kaufmann J; Knipper W; Lantzius-Beninga F
Eur Urol; 1988; 14(3):202-6. PubMed ID: 3133216
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.
Jurincic CD; Engelmann U; Gasch J; Klippel KF
J Urol; 1988 Apr; 139(4):723-6. PubMed ID: 3127600
[TBL] [Abstract][Full Text] [Related]
17. Short schedule intravesical mitomycin preceding transurethral resection for recurrent Ta-T1, G1-G2 bladder cancer.
Maffezzini M; Simonato A; Lodolo C; Raber M; Carmignani G
Tumori; 1995; 81(3):191-3. PubMed ID: 7571026
[TBL] [Abstract][Full Text] [Related]
18. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
van der Meijden AP; DeBruyne FM
Urology; 1988 Mar; 31(3 Suppl):26-9. PubMed ID: 3126592
[TBL] [Abstract][Full Text] [Related]
19. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
Kurth KH; Bouffioux C; Sylvester R; de Pauw M
Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
[No Abstract] [Full Text] [Related]
20. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.
Huland H; Klöppel G; Feddersen I; Otto U; Brachmann W; Hubmann H; Kaufmann J; Knipper W; Lantzius-Beninga F; Huland E
J Urol; 1990 Jul; 144(1):68-71; discussion 71-2. PubMed ID: 2113590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
